Cardiff Oncology prices $10.05 million gross stock and warrant offering

Cardiff Oncology, Inc. filed a prospectus supplement dated July 14, 2026 for an offering of common stock and warrants. Under the deal, the company is offering 8,571,429 shares of common stock together with warrants to purchase up to 8,571,429 shares to several institutional investors.¹ The purchase price for those investors is $1.05 per share and accompanying warrant, under a securities purchase agreement dated July 14, 2026.¹

Separately, the company is offering 721,649 "Insider Shares" with accompanying warrants to certain officers and directors, at a price of $1.455 per share and warrant.¹ Total offering price across both tranches is listed at $10,050,000, with placement agent fees of $703,500 and proceeds before expenses to the company of $9,346,500.¹ After additional offering expenses, the company expects to receive net proceeds of approximately $9.1 million.¹

Cardiff intends to use the net proceeds for continuing operating expenses and working capital.¹ The warrants carry an exercise price of $1.31 per share ($1.33 for insiders), becoming exercisable on the later of six months after issuance or an "Authorized Share Increase Date," with a term of five and one-half years after the initial exercise date.¹ That increase date depends on stockholder approval of a charter amendment raising authorized shares, and the company has agreed to file a proxy statement within 45 days of closing to seek that approval, calling a new meeting every 60 days thereafter if not obtained.¹

H.C. Wainwright & Co., LLC is acting as exclusive placement agent for the offering.¹ Delivery of the shares and warrants is expected on or about July 16, 2026, subject to customary closing conditions.¹ Cardiff's common stock trades on Nasdaq under "CRDF," and closed at $1.31 per share on July 14, 2026.¹